Seeking Research in B cell and Plasma Cell Depletion Programs

CSL is interested in research in the broader area of autoimmunity, with a focus on autoantibody, complement and T cell-mediated diseases. The focus of this search is on removing or downmodulating the autoimmune component causing disease, while simultaneously preserving protective immunity.

Approaches of Particular Interest

- Antibody-based Therapeutics
- Bi-specific (T-cell engaging) Approaches
- Antibody-Drug Conjugates
- Biologics
- Tolerance Induction
- Cell and Gene Therapies

Development Stage

- Opportunities at the levels of basic through to late pre-clinical research
- Targets validated by patient data, biomarker identification and/or animal models would be advantageous
- Multi-omics data welcomed

Submission Information

One-page research summaries are encouraged, plus any relevant non-confidential supporting documents

Out of Scope

- Research focused on Rheumatoid Arthritis (RA) or Oncology are not of interest. However, Oncology or RA-related research will be considered if there are broader applications in autoimmunity.
- Small molecule therapeutic approaches are not within scope. RNA/nucleotide therapeutic approaches will be considered, but are not a priority.

Opportunity for Collaboration

CSL is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case by case basis. Example outcomes include licensing assets, or research collaborations (such as the creation of a joint steering committee consisting of academics and industry experts in the field at CSL).

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spin-out companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 19th October 2020 - 10:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk

© 2020 IN-PART All rights reserved